Revvity, Inc. (RVTY)

NYQ – Цена в реальном времени. Валюта: USD

113.02

-0.51 (-0.45%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

113.24

+0.22 (0.19%)

После закрытия: Jun 26, 2026, 6:59 PM EDT

09.06.2026

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

04.06.2026

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

14.05.2026

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

13.05.2026

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

13.05.2026

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

05.05.2026

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.

05.05.2026

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

13.05.2026

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

05.05.2026

Revvity Announces Financial Results for the First Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.

10.04.2026

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the.

09.04.2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining.

Revvity, Inc. (RVTY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Revvity Announces Financial Results for the First Quarter of 2026

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Revvity Announces Financial Results for the First Quarter of 2026

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Search stocks

Revvity, Inc. (RVTY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Revvity, Inc. (RVTY)

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Revvity Announces Financial Results for the First Quarter of 2026

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

Revvity Announces Financial Results for the First Quarter of 2026

Revvity to Hold Earnings Call on Tuesday, May 5, 2026

Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows